Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX

Laboratory Investigation

Volumn 87, Issue 12, 2007, Pages 1206-1217

  Iakovlev, Vladimir V ^a   Pintilie, Melania ^a   Morrison, Andrew ^a   Fyles, Anthony W ^a,b   Hill, Richard P ^a,b   Hedley, David W ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Carbonic anhydrase IX; Cervical carcinoma; Heterogeneity; Hypoxia; Sampling theory; Tissue microarrays

Indexed keywords

CARBONATE DEHYDRATASE IX; MOLECULAR MARKER;

ANALYSIS OF VARIANCE; ANALYTIC METHOD; ARTICLE; CELL HETEROGENEITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE MARKER; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPOTHESIS; HYPOXIA; IMAGE ANALYSIS; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MEDICAL RESEARCH; OXIMETRY; OXYGEN TENSION; OXYGENATION; PRIORITY JOURNAL; RELIABILITY; SAMPLING; STAINING; TISSUE MICROARRAY; TUMOR; TUMOR BIOPSY; UTERINE CERVIX CARCINOMA;

ANTIGENS, NEOPLASM; BIOPSY; CARBONIC ANHYDRASES; CELL HYPOXIA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; OXYGEN; PARTIAL PRESSURE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 36248948574     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700680     Document Type: Article

References (54)

1. Bachtiary B, Boutros PC, Pintilie M, et al. Gene expression profiling in cervical cancer: an exploration of intratumor heterogeneity. Clin Cancer Res 2006;12:5632-5640.
2. Ohmori H, Fujii K, Sasahira T, et al. Determinants for prediction of malignant potential by metalloproteinase:E-cadherin ratio in prostate core needle biopsy. Pathobiology 2006;73:98-104.
3. Tonotsuka N, Hosoi Y, Miyazaki S, et al. Heterogeneous expression of DNA-dependent protein kinase in esophageal cancer and normal epithelium. Int J Mol Med 2006;18:441-447.
4. Van Meter T, Dumur C, Hafez N, et al. Microarray analysis of MRI-defined tissue samples in glioblastoma reveals differences in regional expression of therapeutic targets. Diagn Mol Pathol 2006;15:195-205.
5. Kimura M, Tsuda H, Morita D, et al. Usefulness and limitation of multiple endoscopic biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients with gastric adenocarcinoma. Jpn J Clin Oncol 2005;35:324-331.
6. Chapman JA, Wolman E, Wolman SR, et al. Assessing genetic markers of tumour progression in the context of intratumour heterogeneity. Cytometry 1998;31:67-73.
7. Lewis JT, Ketterling RP, Halling KC, et al. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. Am J Clin Pathol 2005;124:273-281.
8. Blackhall FH, Pintilie M, Wigle DA, et al. Stability and heterogeneity of expression profiles in lung cancer specimens harvested following surgical resection. Neoplasia 2004;6:761-767.
9. Pacifico MD, Grover R, Richman P, et al. Validation of tissue microarray for the immunohistochemical profiling of melanoma. Melanoma Res 2004;14:39-42.
10. Gomaa W, Ke Y, Fujii H, et al. Tissue microarray of head and neck squamous carcinoma: validation of the methodology for the study of cutaneous fatty acid-binding protein, vascular endothelial growth factor, involucrin and Ki-67. Virchows Arch 2005;447:701-709.
11. Singh SS, Qaqish B, Johnson JL, et al. Sampling strategy for prostate tissue microarrays for Ki-67 and androgen receptor biomarkers. Anal Quant Cytol Histol 2004;26:194-200.
12. Donati V, Faviana P, Dell'omodarme M, et al. Applications of tissue microarray technology in immunohistochemistry: a study on c-kit expression in small cell lung cancer. Hum Pathol 2004;35:1347-1352.
13. Gillett CE, Springall RJ, Barnes DM, et al. Multiple tissue core arrays in histopathology research: a validation study. J Pathol 2000;192:549-553.
14. Merseburger AS, Kuczyk MA, Serth J, et al. Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. Oncol Rep 2003;10:223-228.
15. Goethals L, Perneel C, Debucquoy A, et al. A new approach to the validation of tissue microarrays. J Pathol 2006;208:607-614.
16. Glockner S, Buurman H, Kleeberger W, et al. Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer. Lab Invest 2002;82:1419-1426.
17. Chung GG, Zerkowski MP, Ghosh S, et al. Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Lab Invest 2007;87:662-669.
18. Ruiz C, Seibt S, Al Kuraya K, et al. Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer 2006;118:2190-2194.
19. Thrall DE, Rosner GL, Azuma C, et al. Hypoxia marker labeling in tumor biopsies: quantification of labeling variation and criteria for biopsy sectioning. Radiother Oncol 1997;44:171-176.
20. Cline JM, Rosner GL, Raleigh JA, et al. Quantification of CCI-103F labeling heterogeneity in canine solid tumors. Int J Radiat Oncol Biol Phys 1997;37:655-662.
21. Cline JM, Thrall DE, Rosner GL, et al. Distribution of the hypoxia marker CCI-103F in canine tumors. Int J Radiat Oncol Biol Phys 1994;28:921-933.
22. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941-943.
23. Brizel DM, Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-289.
24. Hockel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-4515.
25. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-276.
26. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91.
27. Nordsmark M, Loncaster J, Aquino-Parsons C, et al. Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiother Oncol 2003;67:35-44.
28. Nordsmark M, Loncaster J, Chou SC, et al. Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma. Int J Radiat Oncol Biol Phys 2001;49:581-586.
29. Maseide K, Kandel RA, Bell RS, et al. Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. Clin Cancer Res 2004;10:4464-4471.
30. Chia SK, Wykoff CC, Watson PH, et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 2001;19:3660-3668.
31. Hoskin PJ, Sibtain A, Daley FM, et al. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer 2003;89:1290-1297.
32. Vordermark D, Brown JM. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? Strahlenther Onkol 2003;179:801-811.
33. Loncaster JA, Harris AL, Davidson SE, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: Correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001;61:6394-6399.
34. Hedley D, Pintilie M, Woo J, et al. Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin Cancer Res 2003;9:5666-5674.
35. Mayer A, Hockel M, Vaupel P. Carbonic anhydrase IX expression and tumor oxygenation status do not correlate at the microregional level in locally advanced cancers of the uterine cervix. Clin Cancer Res 2005;11:7220-7225.
36. Jankovic B, Aquino-Parsons C, Raleigh JA, et al. Comparison between pimonidazole binding, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix. Cytometry B Clin Cytom 2006;70:45-55.
37. Fyles A, Milosevic M, Hedley D, et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002;20:680-687.
38. Hedley D, Pintilie M, Woo J, et al. Up-regulation of the redox mediators thioredoxin and apurinic/apyrimidinic excision (APE)/Ref-1 in hypoxic microregions of invasive cervical carcinomas, mapped using multispectral, wide-field fluorescence image analysis. Am J Pathol 2004;164:557-565.
39. Vukovic V, Haugland HK, Nicklee T, et al. Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res 2001;61:7394-7398.
40. Måseide K, Pintilie M, Kandel R, et al. Can sparsely and heterogeneously expressed proteins be detected using tissue microarrays? A simulation study of the hypoxia marker carbonic anhydrase IX (CA IX) in human soft tissue sarcoma. Pathology Research and Practice 2007, (in press).
41. Airley RE, Loncaster J, Raleigh JA, et al. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer 2003;104:85-91.
42. Troost EG, Bussink J, Kaanders JH, et al. Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines. Radiother Oncol 2005;76:194-199.
43. Goethals L, Debucquoy A, Perneel C, et al. Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers. Int J Radiat Oncol Biol Phys 2006;65:246-254.
44. Dubois L, Landuyt W, Haustermans K, et al. Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry. Br J Cancer 2004;91:1947-1954.
45. Beasley NJ, Wykoff CC, Watson PH, et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 2001;61:5262-5267.
46. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000;60:7075-7083.
47. Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, et al. Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res 2005;65:7259-7266.
48. Olive PL, Aquino-Parsons C, MacPhail SH, et al. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 2001;61:8924-8929.
49. Olive PL, Banath JP, Aquino-Parsons C. Measuring hypoxia in solid tumours - is there a gold standard? Acta Oncol 2001;40:917-923.
50. Mayer A, Hockel M, Vaupel P. Endogenous hypoxia markers in locally advanced cancers of the uterine cervix: reality or wishful thinking? Strahlenther Onkol 2006;182:501-510.
51. Le QT, Chen E, Salim A, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 2006;12:1507-1514.
52. Mayer A, Hockel M, Vaupel P. Carbonic anhydrase IX expression and tumor oxygenation status do not correlate at the microregional level in locally advanced cancers of the uterine cervix. Clin Cancer Res 2005;11:7220-7225.
53. 2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study. Radiother Oncol 2006;80:123-131.
54. Ruiz C, Seibt S, Al Kuraya K, et al. Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer 2006;118:2190-2194.